Ibrutinib Improves Outcomes in CLL/SLL
This video examines a phase III trial of ibrutinib in combination with bendamustine and rituximab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.
In this video, Asher A. Chanan-Khan, MD, of the Mayo Clinic in Jacksonville, Florida, discusses a phase III trial of ibrutinib in combination with bendamustine and rituximab in patients with previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
The trial’s results (abstract LBA7005) were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting held May 29–June 2 in Chicago.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
Related Content
